Corvidane
Corvidane is developing Corvida™ for FDA drug approval to prevent heart and liver diseases, which are the leading causes of death worldwide. Corvida™ is made of fatty acids, specifically Omega-7 and Omega-9, aimed at improving lipid metabolism and reducing inflammation to target diseases such as Atherosclerosis and MASLD/MASH.
Industries
manufacturing
pharmaceutical
therapeutics
Nr. of Employees
small (1-50)
Products
Fatty-acid-based therapeutic candidate for cardiovascular and liver disease
A therapeutic candidate composed of omega-7 and omega-9 fatty acids intended to improve lipid metabolism and provide anti-inflammatory effects to prevent or treat atherosclerosis and MASLD/MASH.
Fatty-acid-based therapeutic candidate for cardiovascular and liver disease
A therapeutic candidate composed of omega-7 and omega-9 fatty acids intended to improve lipid metabolism and provide anti-inflammatory effects to prevent or treat atherosclerosis and MASLD/MASH.
Expertise Areas
- Fatty-acid-based drug development
- Lipid metabolism modulation
- Anti-inflammatory pharmacology
- Cardiovascular therapeutics (atherosclerosis)
Key Technologies
- Fatty-acid-based therapeutic platform
- Lipid-modulating pharmacology
- Inflammation-targeting pharmacology
- Lipid-based drug formulation